Business
Innocan Pharma Announces Promising Translational Evidence from a Pain Relief Study of Repeated LPT-CBD Administration in Goats
Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled "Liposomal-synthetic-cannabidiol: preliminary translational evidence of efficacy, tolerability and pharmacokinetics following repeated subcutaneous injections in two goats" in the peer reviewed esteemed journal Frontiers in Pharmacology (https://doi.org/10.3389/fphar.2025.168922
About this update from Innocan Pharma Corporation
[{"type":"text","content":"HERZLIYA, Israel and CALGARY, Alberta, Nov. 24, 2025 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled "Liposomal-synthetic-cannabidiol: preliminary translational evidence of efficacy, tolerability and pharmacokinetics following repeated subcutaneous injections in two goats" in the peer reviewed esteemed journal Frontiers in Pharmacology (https://doi.org/10.3389/fphar.2025.1689226) (1).","length":606,"tagName":"p"},{"type":"image","alt":"Figure #1: Graphic abstract","displaySize":"","headline":null,"caption":"Figure #1: Graphic abstract","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":111,"url":"https://media.zenfs.com/en/cnwgroup.com/fc67be3b1673948a3b7c24bfdbd1dc43"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5tSw28CtBCqGCmFe0DPCrw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE5NjtjZj13ZWJw/https://media.zenfs.com/en/cnwgroup.com/fc67be3b1673948a3b7c24bfdbd1dc43","width":400,"height":111}},"href":"https://mma.prnewswire.com/media/2831263/Graphic_abstract.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Two goats suffering from chronic and disabling painful condition were treated with subcutaneous Synthetic Liposomal Cannabidiol (LPT-CBD, 5 mg/kg) injections every six weeks for 10 months. Throughout the study, serial blood sampling was performed to assess CBD and its metabolite plasma concentrations and to evaluate hematological and biochemical profiles before and up to six weeks following each administration. Efficacy was assessed by the caregivers via quality of life (QoL) weekly scoring, and adverse effects were monitored. Key findings include:","length":554,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Repeated LPT-CBD injections (7 injections per goat) maintained sustained CBD plasma concentrations consistent with a slow-release pharmacokinetic profile.","length":159,"tagName":"p"}]},{"val":[{"type":"text","content":"Favorable drug tolerability was observed throughout the study with no recorded adverse events.","length":94,"tagName":"p"}]},{"val":[{"type":"text","content":"In contrast to repeated oral CBD consumption in hu...